Male sex | 63 (85.1) | 159 (83.7) | 0.8 |
Risk factor(s) for HIV infection |
Injection drug use only | 23 (31.1) | 38 (20.0) | |
MSM only | 11 (15.9) | 38 (20.0) | |
Injection drug use + MSM | 10 (13.5) | 23 (12.1) | |
Other | 23 (31.1) | 77 (44.5) | |
Unknown | 7 (9.5) | 14 (7.4) | 0.2 |
Age at first clinic visit, yr, median (Q1–Q3) | 42 (38–50) | 46 (41–54) | 0.005 |
Year of clinic enrolment |
2004–2005 | 40 (54.0) | 79 (41.6) | |
2006–2009 | 21 (28.4) | 85 (44.7) | |
2010–2014 | 13 (17.6) | 26 (13.7) | 0.05 |
Baseline CD4 count, cells × 106/L‡ |
< 50 | 33 (44.6) | 15 (7.9) | |
50–199 | 21 (28.4) | 50 (26.3) | |
200–349 | 7 (9.5) | 49 (25.8) | |
≥ 350 | 13 (17.6) | 76 (40.0) | < 0.001 |
Baseline plasma viral load, copies/mL‡ |
< 50 | 11 (14.9) | 71 (37.4) | |
50–99 999 | 37 (50.0) | 84 (44.2) | |
≥ 100 000 | 26 (35.1) | 35 (18.4) | < 0.001 |
ART (ever during study period) | 64 (86.5) | 175 (92.1) | 0.2 |
Latest CD4 count, cells × 106/L§ |
< 50 | 36 (52.2) | 5 (2.7) | |
50–199 | 19 (27.5) | 57 (30.6) | |
200–349 | 6 (8.7) | 44 (23.7) | |
≥ 350 | 8 (11.6) | 80 (43.0) | < 0.001 |
Latest plasma viral load, copies/mL§ |
< 50 | 22 (32.4) | 117 (62.9) | |
50–99 999 | 27 (39.7) | 55 (29.6) | |
≥ 100 000 | 19 (27.9) | 14 (7.5) | < 0.001 |
Calendar period at time of death |
2004–2005 | 15 (20.3) | 15 (7.9) | |
2006–2007 | 22 (29.7) | 28 (14.7) | |
2008–2009 | 10 (13.5) | 35 (18.4) | |
2010–2011 | 10 (13.5) | 31 (16.3) | |
2012–2013 | 9 (12.2) | 41 (21.6) | |
2014–2015 | 8 (10.8) | 40 (21.0) | 0.001 |
Age at death, yr, median (Q1–Q3) | 45 (39–52) | 51 (44–59) | < 0.001 |
Hepatitis virus infection |
Chronic hepatitis B | 1 (1.4) | 9 (4.7) | 0.5 |
Chronic hepatitis C | 12 (16.2) | 49 (25.8) | 0.4 |
AIDS-related illness (yr before death) | 52 (70.3) | 42 (22.1) | < 0.001 |
Visit constancy (first yr), % |
< 75 | 27 (45.8) | 83 (47.4) | |
≥ 75 | 32 (54.2) | 92 (52.6) | 0.4 |
ART adherence (≥ 95%; first yr) | 10 (13.5) | 69 (36.3) | 0.007 |